Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 1, 2011, Pages 89-95

  Pachon Ibanez M E ^a   Ribes, S ^a   Dominguez M A ^a   Fernandez R ^a   Tubau, F ^a   Ariza, J ^a   Gudiol, F ^a   Cabellos, C ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; IMIPENEM; LINEZOLID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLINICAL PRACTICE; COLONY FORMING UNIT; CONTROLLED STUDY; DISK DIFFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PERITONEAL FLUID; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; BACTEREMIA; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FOSFOMYCIN; HUMANS; IMIPENEM; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 78751581742     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-1058-0     Document Type: Article

References (39)

1. AW Karchmer 2000 Nosocomial bloodstream infections: organisms, risk factors, and implications Clin Infect Dis 31 Suppl 4 S139 S143 10.1086/314078 11017863 (Pubitemid 32291121)
2. M Falcone P Serra M Venditti 2009 Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians Eur J Intern Med 20 343 347 10.1016/j.ejim.2008.08.016 19524170
3. R Geisel FJ Schmitz L Thomas G Berns O Zetsche B Ulrich AC Fluit H Labischinsky W Witte 1999 Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area J Antimicrob Chemother 43 846 848 1:STN:280:DyaK1Mzjt1equw%3D%3D 10.1093/jac/43.6.846 10404328 (Pubitemid 29273739)
4. K Hiramatsu H Hanaki T Ino K Yabuta T Oguri FC Tenover 1997 Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 135 136 1:CAS:528: DyaK2sXltVCit7w%3D 10.1093/jac/40.1.135 9249217 (Pubitemid 27341646)
5. MN Kim CH Pai JH Woo JS Ryu K Hiramatsu 2000 Vancomycin-intermediate Staphylococcus aureus in Korea J Clin Microbiol 38 3879 3881 1:STN:280:DC%2BD3M%2FisVKisg%3D%3D 11015427
6. Y Maor G Rahav N Belausov D Ben-David G Smollan N Keller 2007 Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center J Clin Microbiol 45 1511 1514 1:CAS:528:DC%2BD2sXmsFOmtLY%3D 10.1128/JCM.01262-06 17344363 (Pubitemid 46762406)
7. F Bert J Clarissou F Durand D Delefosse C Chauvet P Lefebvre N Lambert C Branger 2003 Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients J Clin Microbiol 41 5147 5152 1:CAS:528: DC%2BD3sXpvVyhsb4%3D 10.1128/JCM.41.11.5147-5152.2003 14605151 (Pubitemid 37429928)
8. GA Ayliffe 1997 The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus Clin Infect Dis 24 Suppl 1 S74 S79 8994782
9. Centers for Disease Control and Prevention (CDC) 2002 Staphylococcus aureus resistant to vancomycin-United States, 2002 MMWR Morb Mortal Wkly Rep 51 565 567
10. MC Enright DA Robinson G Randle EJ Feil H Grundmann BG Spratt 2002 The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) Proc Natl Acad Sci USA 99 7687 7692 1:CAS:528:DC%2BD38XktlCrs7s%3D 10.1073/pnas.122108599 12032344 (Pubitemid 34568752)
11. AV Groom DH Wolsey TS Naimi K Smith S Johnson D Boxrud KA Moore JE Cheek 2001 Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community JAMA 286 1201 1205 1:STN:280:DC%2BD3MrhvVegsA%3D%3D 10.1001/jama.286.10.1201 11559265
12. H Grundmann A Tami S Hori M Halwani R Slack 2002 Nottingham Staphylococcus aureus population study: prevalence of MRSA among elderly people in the community Br Med J 324 1365 1366 10.1136/bmj.324.7350.1365 (Pubitemid 34628006)
13. FM Hussain S Boyle-Vavra RS Daum 2001 Community-acquired methicillin-resistant Staphylococcus aureus colonization in healthy children attending an outpatient pediatric clinic Pediatr Infect Dis J 20 763 767 1:STN:280:DC%2BD3Mnoslyrsg%3D%3D 11734738
14. FD Lowy 1998 Staphylococcus aureus infections N Engl J Med 339 520 532 1:STN:280:DyaK1czmtlKltw%3D%3D 10.1056/NEJM199808203390806 9709046 (Pubitemid 28384886)
15. TS Naimi KH LeDell DJ Boxrud AV Groom CD Steward SK Johnson JM Besser C O'Boyle RN Danila JE Cheek MT Osterholm KA Moore KE Smith 2001 Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998 Clin Infect Dis 33 990 996 1:STN:280:DC%2BD3Mrkt1Ogsg%3D%3D 10.1086/322693 11528570 (Pubitemid 32907100)
16. RH Drew 2007 Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections Pharmacotherapy 27 227 249 1:CAS:528:DC%2BD2sXitlyjsb8%3D 10.1592/phco.27.2.227 17253914 (Pubitemid 46214584)
17. F Marco CG de la Mària Y Armero E Amat D Soy A Moreno A del Río M Almela CA Mestres JM Gatell MT Jiménez de Anta JM Miró Hospital Clinic Experimental Endocarditis Study Group 2008 Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus Antimicrob Agents Chemother 52 2538 2543 1:CAS:528:DC%2BD1cXot1Ohs7Y%3D 10.1128/AAC.00510-07 18426900 (Pubitemid 351915686)
18. O Murillo C Garrigós ME Pachón G Euba R Verdaguer C Cabellos J Cabo F Gudiol J Ariza 2009 Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 4252 4257 1:CAS:528:DC%2BD1MXht1Kkur3L 10.1128/AAC.00208-09 19635963
19. M Gobernado 2003 Fosfomycin Rev Esp Quimioter 16 15 40 1:STN:280:DC%2BD3s3ivV2jug%3D%3D 12750755
20. SS Patel JA Balfour HM Bryson 1997 Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections Drugs 53 637 656 1:CAS:528:DyaK2sXisFGgurs%3D 10.2165/00003495- 199753040-00007 9098664
21. WA Craig SC Ebert 1989 Protein binding and its significance in antibacterial therapy Infect Dis Clin North Am 3 407 414 1:STN:280: DyaL1MzmtVCmsQ%3D%3D 2671130
22. JW Mouton U Theuretzbacher WA Craig PM Tulkens H Derendorf O Cars 2008 Tissue concentrations: do we ever learn? J Antimicrob Chemother 61 235 237 1:CAS:528:DC%2BD1cXptlGltg%3D%3D 10.1093/jac/dkm476 18065413
23. P Arca G Reguera C Hardisson 1997 Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey J Antimicrob Chemother 40 393 399 1:CAS:528:DyaK2sXmtlektLg%3D 10.1093/jac/40.3.393 9338493 (Pubitemid 27437960)
24. K Grif MP Dierich K Pfaller PA Miglioli F Allerberger 2001 In vitro activity of fosfomycin in combination with various antistaphylococcal substances J Antimicrob Chemother 48 209 217 1:CAS:528:DC%2BD3MXmsVeisbg%3D 10.1093/jac/48.2.209 11481290
25. H Nakazawa Y Kikuchi T Honda T Isago M Nozaki 2003 Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin J Infect Chemother 9 304 309 1:CAS:528:DC%2BD3sXhtVSjsbzN 10.1007/s10156-003-0266-2 14691650 (Pubitemid 38031325)
26. JM Sahuquillo Arce E Colombo Gainza A Gil Brusola R Ortiz Estévez E Cantón M Gobernado 2006 In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus Rev Esp Quimioter 19 252 257 1:STN:280:DC%2BD28nmvVehsQ%3D%3D 17099793
27. P Chavanet E Muggeo A Waldner S Dijoux D Caillot H Portier 1990 Synergism between cefotaxime and fosfomycin in the therapy of methicillin and gentamicin resistant Staphylococcus aureus infection in rabbits Eur J Clin Microbiol Infect Dis 9 271 275 1:CAS:528:DyaK3cXltVykur0%3D 10.1007/BF01968058 2351143
28. Marco F, Miro JM, Del Rio A, García C, Gavaldá J, Dern E, Almela M, Soy M, Torra M, Moreno A, Pahissa A, Gatell JM, Jiménez De Anta MT (2000) Efficacy of Fosfomycin (Fos) plus Imipenem (Imi) or Ceftriaxone (Cro) Combinations in the Treatment of Experimental Endocarditis (EE) due to Methicillin-Resistant Staphylococcus aureus (MRSA). Abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000, p. 58
29. K Morikawa M Nonaka Y Yoshikawa I Torii 2005 Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model Int J Antimicrob Agents 25 44 50 1:CAS:528:DC%2BD2cXhtFGhsLzO 10.1016/j.ijantimicag.2004.07.015 15620825 (Pubitemid 40023345)
30. A Rodríguez MV Vicente T Olay 1987 Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 31 1444 1445 3674852
31. García de la María C, Marco F, Miro JM, Armero Y, Jiménez-Alzate MP, Díaz ME, Moreno A, Almela M, Benito N, Claramonte X, Torra M, Mestres CA, Perez N, Gatell JM, Jiménez de Anta MT (2003) Efficacy of Fosfomycin (Fos) plus Imipenem (Imi) or Ceftriaxone (Cro) Combination in the Treatment of Experimental Endocarditis (EE) Due to Methicillin Resistant (MRSA) or Glycopeptide Intermediate Resistant (GISA) Staphylococcus aureus. Abstract of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003, p. 1091
32. N Aritaka H Hanaki L Cui K Hiramatsu 2001 Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin Antimicrob Agents Chemother 45 1292 1294 1:CAS:528:DC%2BD3MXit1Omsb4%3D 10.1128/AAC.45.4.1292-1294.2001 11257050 (Pubitemid 32232984)
33. J Ariza M Pujol J Cabo C Peña N Fernández J Liñares J Ayats F Gudiol 1999 Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin Lancet 353 1587 1588 1:STN:280:DyaK1M3msFCgsw%3D%3D 10.1016/S0140-6736(99)01017-X 10334262 (Pubitemid 29219213)
34. Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A6, 6th edn. CLSI, Wayne, PA
35. O Murillo A Doménech A Garcia F Tubau C Cabellos F Gudiol J Ariza 2006 Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus Antimicrob Agents Chemother 50 4011 4017 1:CAS:528:DC%2BD28XhtlWksrvO 10.1128/AAC.00523-06 17015630 (Pubitemid 44865143)
36. A Doménech S Ribes C Cabellos MA Domínguez A Montero J Liñares J Ariza F Gudiol 2004 A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections Microb Drug Resist 10 346 353 10.1089/mdr.2004.10.346 15650381
37. SS Rotun V McMath DJ Schoonmaker PS Maupin FC Tenover BC Hill DM Ackman 1999 Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia Emerg Infect Dis 5 147 149 1:CAS:528:DyaK1MXhvVSjtrk%3D 10.3201/eid0501.990118 10081683
38. C Quentin S Saivin C Lafferriere P Noury C Bebear 1987 In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method Drugs Exp Clin Res 13 219 224 1:CAS:528:DyaL2sXltFams7g%3D 3476291 (Pubitemid 17100742)
39. E Rubinstein S Cammarata T Oliphant R Wunderink Linezolid Nosocomial Pneumonia Study Group 2001 Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study Clin Infect Dis 32 402 412 1:CAS:528: DC%2BD3MXhs1Whur0%3D 10.1086/318486 11170948 (Pubitemid 32173626)